Format

Send to

Choose Destination
Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787.

Targeting the cancer kinome through polypharmacology.

Author information

1
Zachary A. Knight is at The Rockefeller University, New York, New York 10065, USA.

Abstract

Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.

PMID:
20094047
PMCID:
PMC2880454
DOI:
10.1038/nrc2787
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center